2-(2-甲氧基丙基-2-基)吡咯烷 | 160142-25-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: 2-(2-甲氧基丙基-2-基)吡咯烷
• 英文名称: 2-(2-Methoxypropan-2-yl)pyrrolidine
• CAS: 160142-25-6
• 化学式: C₈H₁₇NO
• 分子量: 143.23
• InChiKey: ZPGUMFCNPREQSF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090
• 包装等级：
  III
• 危险类别：
  8
• 危险性防范说明：
  P260,P264,P270,P280,P301+P330+P331,P303+P361+P353,P304+P340,P305+P351+P338,P310,P363,P405,P501
• 危险品运输编号：
  2735
• 危险性描述：
  H302,H314

文献信息

• [EN] 6-HETEROCYCLYL-4-MORPHOLIN-4-YLPYRIDINE-2-ONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETES<br/>[FR] COMPOSÉS 6-HÉTÉROCYCLYL-4-MORPHOLIN-4-YLPYRIDINE-2-ONE UTILISÉS POUR LE TRAITEMENT DU CANCER ET DU DIABÈTE
  申请人：SPRINT BIOSCIENCE AB

  公开号：WO2017140843A1

  公开（公告）日：2017-08-24

  The invention provides novel 6-heterocyclyl-4-morpholin-4-yl-pyridine-2-one compounds of formula (I), pharmaceutical compositions containing such compounds, and methods for using such compounds in treatment of diseases including cancer, diabetes, inflammatory disease, neurodegenerative disorders, cardiovascular disorders and viral infections; wherein R1, R2, R3 and A are as defined in the specification.

  该发明提供了公式（I）的新型6-杂环基-4-吗啡啉-4-基吡啶-2-酮化合物，包含该化合物的药物组合物，以及使用该化合物治疗癌症、糖尿病、炎症性疾病、神经退行性疾病、心血管疾病和病毒感染等疾病的方法；其中R1、R2、R3和A如规范中所定义。
• Carbonyl substituted pyrazoline compounds, their preparation and use as CB1 receptor modulators
  申请人：LABORATORIOS DEL DR. ESTEVE, S.A.

  公开号：EP1743888A1

  公开（公告）日：2007-01-17

  The present invention relates to substituted pyrazoline compounds, methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals.

  本发明涉及取代吡唑啉化合物，其制备方法，包含这些化合物的药物以及它们用于制备用于治疗人类和动物的药物的用途。
• Active substance combination for the treatment of diabetes
  申请人：Laboratorios del Dr. Esteve S.A.

  公开号：EP1946778A1

  公开（公告）日：2008-07-23

  The present invention relates to an active substance combination comprising at least one substituted pyrazoline compound and at least one drug, used to treat diabetes, a medicament comprising said active substance combination, a pharmaceutical formulation comprising said active substance combination and the use of said active substance combination for the manufacture of a medicament.

  本发明涉及一种活性物质组合，包括至少一种取代吡唑啉化合物和至少一种药物，用于治疗糖尿病，包括该活性物质组合的药物、包括该活性物质组合的制药配方以及利用该活性物质组合制造药物的用途。
• Substituted pyrazoline for preventing weight gain
  申请人：Laboratorios del Dr. Esteve S.A.

  公开号：EP1946777A1

  公开（公告）日：2008-07-23

  The present invention relates to an active substance combination comprising at least one substituted pyrazoline compound and at least one drug, known to produce weight-gain as a side effect, a medicament comprising said active substance combination, a pharmaceutical formulation comprising said active substance combination and the use of said active substance combination for the manufacture of a medicament.

  本发明涉及一种活性物质组合，包括至少一种取代吡唑啉化合物和至少一种药物，该药物以体重增加作为副作用而知名，包括所述活性物质组合的药物、包括所述活性物质组合的药物制剂、以及利用所述活性物质组合制造药物。
• Heterocyclyl-substituted pyrazoline compounds, their preparation and use as medicaments
  申请人：LABORATORIOS DEL DR. ESTEVE, S.A.

  公开号：EP1743894A1

  公开（公告）日：2007-01-17

  The present invention relates to heterocyclyl-substituted pyrazoline compounds, methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals.

  本发明涉及杂环基取代的吡唑啉化合物、其制备方法、包含这些化合物的药物以及它们用于制备用于治疗人类和动物的药物的用途。